• 1. Stereoselective total syntheses of atrochrysone, torosachrysone and related 3,4-dihydroanthracen-1(2H?)-ones
  Michael Müller,Kai Lamottke,Erich L?w,Eva Magor-Veenstra,Wolfgang Steglich J. Chem. Soc. Perkin Trans. 1 2000 2483
• 2. Decorated traditional cellulose with nanoscale chiral metal–organic frameworks for enhanced enantioselective capture
  Yun Guo,Ling Zhang,Kexuan Wang,Ajuan Yu,Shusheng Zhang,Gangfeng Ouyang Chem. Commun. 2021 57 10343
• 3. Stereocontrol in organic synthesis using silicon-containing compounds. A synthesis of nonactin
  Ian Fleming,Sunil K. Ghosh J. Chem. Soc. Perkin Trans. 1 1998 2733
• 4. An iron variant of the Noyori hydrogenation catalyst for the asymmetric transfer hydrogenation of ketones
  Shangfei Huo,Qingwei Wang,Weiwei Zuo Dalton Trans. 2020 49 7959
• 5. An iron variant of the Noyori hydrogenation catalyst for the asymmetric transfer hydrogenation of ketones
  Shangfei Huo,Qingwei Wang,Weiwei Zuo Dalton Trans. 2020 49 7959

• Solvents and Organic Chemicals Organic Compounds Benzenoids Naphthalenes Naphthalenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Naphthalenes
• Other Chemical Reagents

Recent Advances in the Study of (R)-1-(Naphthalen-1-yl)ethanol (CAS: 42177-25-3) in Chemical Biology and Pharmaceutical Research

(R)-1-(Naphthalen-1-yl)ethanol (CAS: 42177-25-3) is a chiral alcohol derivative that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This compound, characterized by its naphthalene ring and stereogenic center, serves as a versatile intermediate in the synthesis of various biologically active molecules. Recent studies have explored its role in asymmetric synthesis, enzyme inhibition, and drug development, highlighting its importance in modern medicinal chemistry.

One of the key areas of focus has been the use of (R)-1-(Naphthalen-1-yl)ethanol as a chiral building block for the synthesis of enantiomerically pure pharmaceuticals. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the asymmetric synthesis of β-adrenergic receptor antagonists, which are critical in treating cardiovascular diseases. The researchers employed (R)-1-(Naphthalen-1-yl)ethanol as a chiral auxiliary to achieve high enantioselectivity, underscoring its value in stereocontrolled synthesis.

In addition to its synthetic applications, (R)-1-(Naphthalen-1-yl)ethanol has been investigated for its biological activity. A recent preprint on bioRxiv revealed its potential as an inhibitor of cytochrome P450 enzymes, which play a pivotal role in drug metabolism. The study utilized molecular docking and kinetic assays to elucidate the binding interactions between (R)-1-(Naphthalen-1-yl)ethanol and CYP3A4, suggesting its potential as a lead compound for developing novel enzyme inhibitors.

Furthermore, advancements in catalytic systems have enhanced the efficiency of producing (R)-1-(Naphthalen-1-yl)ethanol. A 2022 paper in ACS Catalysis reported a novel biocatalytic approach using engineered ketoreductases to achieve high yields and enantiomeric excess (ee) of (R)-1-(Naphthalen-1-yl)ethanol from its prochiral ketone precursor. This green chemistry approach aligns with the growing demand for sustainable synthetic methods in the pharmaceutical industry.

The pharmacological potential of (R)-1-(Naphthalen-1-yl)ethanol derivatives has also been explored. A collaborative study between academic and industrial researchers, published in European Journal of Medicinal Chemistry in 2023, identified several derivatives with promising anti-inflammatory and anticancer activities. Structure-activity relationship (SAR) studies highlighted the importance of the naphthalene moiety and the hydroxyl group in mediating these effects, providing a foundation for future drug design efforts.

Despite these advancements, challenges remain in optimizing the scalability and cost-effectiveness of (R)-1-(Naphthalen-1-yl)ethanol production. Recent patents filed by major pharmaceutical companies indicate ongoing efforts to address these issues through innovative catalytic processes and fermentation technologies. These developments are expected to further solidify the compound's role in drug discovery and development.

In conclusion, (R)-1-(Naphthalen-1-yl)ethanol (CAS: 42177-25-3) continues to be a molecule of significant interest in chemical biology and pharmaceutical research. Its applications in asymmetric synthesis, enzyme inhibition, and drug development, coupled with recent methodological advancements, position it as a valuable tool for medicinal chemists. Future research is likely to focus on expanding its therapeutic potential and improving synthetic routes to meet industrial demands.

• 79760-52-4(9-Anthracenemethanol, a-1-naphthalenyl-)
• 27544-18-9((S)-(-)-1-(2-Naphthyl)ethanol)
• 7494-58-8(3-Phenanthrenemethanol,a-methyl-)
• 36271-80-4(Benzo[a]pyrene-6-methanol,a-methyl- (9CI))
• 15914-84-8((S)-1-(Naphthalen-1-yl)ethanol)
• 22371-34-2(rac-1-Anthracen-2-yl-ethanol)
• 7512-20-1(1-(Anthracen-9-yl)ethanol)
• 7228-47-9(1-(Naphthalen-2-yl)ethanol)
• 1517-72-2(1-(1-Naphthyl)ethanol)
• 642-28-4(1-Naphthalenemethanol, a-phenyl-)